Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal PHARMACY: Jurnal Farmasi Indonesia (Pharmaceutical Journal of Indonesia) Indonesian Journal of Cancer
Yamsun, Muhammad
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Phyllodes Tumor on Male Breast: A Literature Review Dzulhijar, Naufal; Yamsun, Muhammad
Indonesian Journal of Cancer Vol 18, No 2 (2024): June
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v18i2.1113

Abstract

Background: Phyllodes tumor is a neoplasm from the fibroepithelial lesion and is rare to be found. Hence, there are some case reports that phyllodes tumor also can be found in the male breast. From 1990 until 2020, 13 articles show the phyllodes tumor in the male breast. The incidence of this tumor is 6.92% of all malignancies in the breast and occurs at a younger age, ie 25-30 years. Despite the rare cases of phyllodes tumors on male breasts, this study aims to explore and summarize the risk factors, diagnostic approaches, and treatment used for the cases. Methods: This literature review is synthesized with analysis of the source of information from online databases, such as NCBI, Google Scholar, Science Direct, Elsevier, Springer Nature, Wiley Online Library, World Health Organization, Kementerian Kesehatan Republik Indonesia, and Perhimpunan Onkologi Indonesia (POI). The keywords are “phyllodes tumor on male breast” and “tumor filodes pada pria”. Thirteen articles provided the cases by years of publication later than 2012, but only 7 cases fulfilling inclusion and exclusion criteria were used for analysis. Results: Phyllodes tumors on the male breast would likely appear in those who have gynecomastia or prostate disease and are currently on therapy for the disease. Gynecomastia has the potential to affect an estrogen/androgen imbalance. Several case studies mention that there is an incidence of breast tumors in men who use long-term estrogen therapy. Treatment with bicalutamide for men with prostate cancer can also lead to malignant phyllodes tumors in men. Conclusions: Phyllodes tumors on male breasts are rare cases that need to be understood by physicians for diagnostic approach and effective treatment. The male who have a history of gynecomastia or prostate disease should be cautious as they can develop phyllodes tumors in the future.
Cost-Utility Analysis Addition of Bevacizumab to Standard Chemotherapy in KRAS-mutation Colorectal Cancer Putri, Devi Andiani; Setiawan, Didik; Yamsun, Muhammad
PHARMACY: Jurnal Farmasi Indonesia (Pharmaceutical Journal of Indonesia) Jurnal Pharmacy, Vol. 22 No. 01 Juli 2025
Publisher : Pharmacy Faculty, Universitas Muhammadiyah Purwokerto

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30595/pharmacy.v22i1.24298

Abstract

There is a high incidence of colorectal cancer in Indonesia. Colorectal cancer was ranked fourth with an incidence of 8.6% and a colon cancer mortality rate of 4% while rectal cancer was 3.6% in Indonesia. The addition of Bevacizumab to Standard chemotherapy (FOLFOX/FOLFIRI/XELOX) in KRAS-mutation colorectal cancer patients has better clinical outcomes; however, it has a very high cost in terms of colorectal cancer treatment. The objective of this study was to determine the utility and economic impact of adding Bevacizumab as an adjunct therapy for KRAS-mutation colorectal cancer patients. A Markov model was developed to estimate the Cost-utility analysis (CUA) using a societal perspective. Humanistic outcomes are expressed in the form of QALY (Quality-adjusted life years) using an EQ-5D-5L instrument with an Indonesian value set. Medical expenses data were collected from both RSUP Dr. Sardjito and patients. Utility data were obtained from interviews with 30 patients undergoing chemotherapy at the hospital. This study compared the cost and utility of patients receiving Bevacizumab supplementation or patients receiving standard chemotherapy alone. The societal perspective resulted in a cost-effectiveness ratio (ICER) of US$3.098 per QALY. The addition of Bevacizumab to standard chemotherapy in KRAS-mutation colorectal cancer patients is considerably cost-effective from a societal perspective.
Co-Authors Didik Setiawan Dzulhijar, Naufal Putri, Devi Andiani